Chronic Stress Facilitates the Development of Deep Venous Thrombosis

Tao Dong,1 Yu-Wen Cheng,1 Fei Yang,2 Pei-Wen Sun,1 Chen-Jie Zhu,1 Li Zhu,2 and Guo-Xing Zhang1

1Department of Physiology, Medical College of Soochow University, Suzhou 215003, China
2Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology, MOH Key Lab of Thrombosis and Hemostasis, Jiangsu Institute of Hematology, The First Affiliated Hospital, Soochow University, Suzhou 215003, China

Correspondence should be addressed to Li Zhu; zhul@suda.edu.cn and Guo-Xing Zhang; zhangguoxing@suda.edu.cn

Received 26 February 2015; Revised 22 March 2015; Accepted 27 March 2015

Academic Editor: Hanjun Wang

Copyright © 2015 Tao Dong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The increasing pressure of modern social life intensifies the impact of stress on the development of cardiovascular diseases, which include deep venous thrombosis (DVT). Renal sympathetic denervation has been applied as one of the clinical approaches for the treatment of drug-resistant hypertension. In addition, the close relationship between oxidative stress and cardiovascular diseases has been well documented. The present study is designed to explore the mechanism by which the renal sympathetic nerve system and the oxidative stress affect the blood coagulation system in the development of DVT. Chronic foot shock model in rats was applied to mimic a state of physiological stress similar to humans. Our results showed that chronic foot shock procedure could promote DVT which may be through the activation of platelets aggregation. The aggravation of DVT and activation of platelets were alleviated by renal sympathetic denervation or antioxidant (Tempol) treatment. Concurrently, the denervation treatment could also reduce the levels of circulating oxidation factors in rats. These results demonstrate that both the renal sympathetic nerve system and the oxidative stress contribute to the development of DVT in response to chronic stress, which may provide novel strategy for treatment of clinic DVT patients.

1. Introduction

Deep venous thrombosis (DVT) is a common cardiovascular disease associated sequelae, pulmonary embolism, which is the third most common cause of death from cardiovascular diseases after heart attack and stroke. A slow blood flow, vein wall damage, and a hypercoagulable state are the three principal risk factors for DVT development. Consequently, anticoagulants and thrombolytics are the two main treatments for clinical DVT patients. The triad of risk factors predisposing to thrombus formation, postulated by Virchow, includes changes in the ratio between blood components, the integrity of the vessel wall, and the blood flow rate. The blood coagulation system plays a key role in protecting mammals against lethal bleeding. In all forms of thrombosis, coagulation and inflammation are the two principal pathways acting together to coordinate the body’s responses to injury [1, 2].

Over the past few decades, psychological factors, such as stress and depression, have been recognized as important factors affecting human health [3]. Long periods of anxiety will induce the development of cardiovascular diseases. Moreover, by occurring simultaneously, depression and anxiety will aggravate the development of cardiovascular disease even further. In addition, stress and other psychological factors have been demonstrated to be closely related to the occurrence of stroke and myocardial infarction [4]. Numerous studies also have shown that stress can cause long-lasting structural damage to tissues and organs [5]. The chronic electric foot shock procedure has been characterized as a model of uncontrollable and unpredictable psychological stress [6], which has been demonstrated to be able to induce increase in systolic blood pressure [7–9]. However, there is still no report related to the effects of chronic shock on the development of DVT.
The role of sympathetic renal nerve in the development of hypertension has been demonstrated in both experimental and clinical observations [10, 11]. There are two types of sympathetic renal nerve: renal afferent nerves and renal efferent nerve. The afferent sympathetic fibers originate from the kidneys, and by modulating central sympathetic outflow they directly modify neurogenic hypertension. At the same time, the efferent nerve enhances sodium and water retention, stimulates renin release, and alters renal blood flow [10–13]. In this way, both short-term and long-term blood pressure could be influenced by renal sympathetic nerve [13]. Clinical studies have reported the beneficial effects of renal sympathetic denervation in patients with refractory hypertension [9]. In addition to the lowering effect of denervation on blood pressure, additional benefits have also been reported in cardiovascular diseases, diabetes [9], renal dysfunction, cardiac hypertrophy [1], heart failure [9], and arrhythmias [14]. Hypertension, a major risk factor for many diseases, can increase endothelial dysfunction and promote thrombosis and is also closely related to the incidence of cerebrovascular diseases [9]. Therefore, renal sympathetic denervation may provide new strategy in prevention and treatment of cardiovascular diseases under high stress condition.

Recently, experiments show that oxidative stress might be responsible for the change in endothelial function [15]. The increased reactive oxygen species produced by vascular endothelium and circulating blood cells will impair vasomotor and endothelial barrier functions and enhance thrombus formation [16]. Oxidative stress was also found to be a determinant of platelet activation [17], which was the risk factor for atherothrombosis. However, whether chronic stress could affect coagulation system by increasing of oxidative stress is still unknown.

Currently, no reports are directly linking psychological stress with the coagulation system and cerebrovascular diseases. Considering that the activation of the coagulation system has an important influence on both physiological hemostasis and pathological thrombosis [9], we applied foot shock stress model in rats to explore whether chronic could affect the development of DVT and the possible mechanisms involved.

2. Materials and Methods

2.1. Animal Preparation. Ten-week-old male Sprague-Dawley rats, obtained from Shanghai Laboratory Animal Center, were used in this study. Animals were maintained in a 25°C temperature-controlled environment with a 12:12-hour light:dark cycle. Rats exposed to the stress protocol were individually placed into a foot shock stress box, where they received a 4-hour session of electrical foot shock through an electrified grid floor delivering a 5-second long 0.15 mA shock every 30 seconds. The rat renal sympathetic nerve was surgically severed while animals were under a 10% chloral hydrate-induced anesthesia. After a one-week recovery period, the foot shock protocol was started. Tempol (10 mg/kg/day) was administered by intraperitoneal injection after the start of the stress protocol [18–20]. Venous thrombosis was induced under anaesthetized conditions with 10% chloral hydrate as previously described by Leung [21]. Briefly, the abdomen was opened, and the inferior vena cava (IVC), after being carefully separated from the surrounding tissues, was ligated tightly just below the left renal vein using a cotton thread. Then, the abdomen was closed with a double layer of sutures, closing the peritoneum with muscles first and then the skin separately. After twelve hours, the animals were anaesthetized again, the abdomen was reopened, and the plasma and thrombus were collected for further analysis [2]. The present study was performed in conformity with the European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes (Council of Europe number 123, Strasbourg, 1985). All surgical procedures were approved by the Soochow University and performed in accordance with the guidelines for the care and use of animals established by the Soochow University.

2.2. Plasma Corticosterone Levels Measurements. Plasma corticosterone levels were measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (TSZ Elisa, USA).

2.3. Thrombus Weight Measurements. From the reopened abdominal cavity, the ligated segment of the vena cava was removed and opened longitudinally to remove the formed thrombus, which was rinsed and weighed on filter paper.

2.4. Analysis of the Blood Coagulation Parameters. Prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT) were measured using an automated blood coagulation analyzer (Sysmex Corporation CA-50, Japan). From the reopened abdominal cavity, blood (4.5 mL) was collected from the inferior vena cava using a disposable syringe, containing 0.5 mL of a 3.8% sodium citrate solution, and transferred into autoclaved centrifuge tubes. Half of the blood was centrifuged at 3000 rpm for 10 min and the serum was collected. A 0.1 mL serum aliquot was combined to 0.1 mL of PT reagent. After preheating for 20 min, the PT was measured using an automated blood coagulation analyzer, as mentioned above. The APPT and the TT were measured using the same method as the PT.

Platelet aggregation was measured using a platelet aggregation analyzer (Chrono-Log 560 Ca, Germany). After the cavity was reopened, 4.5 mL blood was collected from the inferior vena cava by using a disposable syringe containing with 0.5 mL sodium citrate (3.8%) and then transferred to centrifuge tube. The second half of the blood was centrifuged at 1000 rpm for 10 min to obtain the platelet-rich plasma. The blood remaining in the tube was centrifuged at 3000 rpm for 10 min to prepare the platelet-poor plasma. Then, coagulation of the plasma samples was stimulated using collagen protein and adenosine diphosphate disodium (ADP) (1 mM, 10 mL) as platelet agonists.

2.5. Determination of Plasma Noradrenaline (NA) Concentration. Plasma noradrenaline (NA) levels were measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (TSZ Elisa, USA).
3. Results

3.1. Effect of Shock, Denervation, and Tempol Treatment on the Plasma Corticosterone Concentrations. Plasma corticosterone levels (the marker of stress) were markedly increased in the foot shock group when compared with the control group ($P < 0.05$, Figure 1) and were markedly suppressed in both the denervation plus shock and the Tempol plus shock groups compared with the foot shock alone group ($P < 0.05$, Figure 1). This result indicated that chronic foot shock significantly increased plasma corticosterone when the body was under stress, and both of denervation and Tempol treatment could alleviate the stress state.

3.2. Effect of Shock, Denervation, and Tempol Treatment on the Weight of IVC Ligation-Induced Thrombi. Thrombi were collected 12 hours after IVC ligation and weighted. In the foot shock group, the thrombus weight was significantly increased compared with that of the control group ($P < 0.05$, Figure 2). However, the thrombus weight of the denervation plus shock and Tempol plus shock groups remained unchanged compared with the control group thrombi but was significantly decreased compared with the foot shock group thrombi ($P < 0.05$, Figure 2). These results suggest that chronic shock could facilitate the formation of DVT, while both denervation and Tempol treatment could inhibit stress-induced increase of DVT formation.

3.3. Effect of Shock, Denervation, and Tempol Treatment on Blood Coagulation Parameters. After blood collection from the IVC, blood parameters (PT, APPT, TT, and platelet aggregation) were measured. There was a significant difference in the PT, TT, and platelet aggregation parameters between the control and the foot shock groups. The PT of the foot shock group was lower than that of the control group; however, the TT and platelet aggregation parameters were higher in the foot shock group compared with the control group. In parallel, a significant decrease was observed in the TT and platelet aggregation parameters of the denervation plus shock and Tempol plus shock groups compared with the foot shock group ($P < 0.05$, Table 1 and Figure 3). These results reveal that chronic shock could enhance coagulation system by activation of platelet aggregation.

3.4. Effect of Shock, Denervation, and Tempol Treatment on the Plasma Noradrenaline (NA) Concentrations. Foot shock significantly increased the plasma noradrenaline (NA) levels compared with control group ($P < 0.05$, Figure 4). The plasma NA levels in the denervation plus shock and Tempol plus shock group were significantly suppressed compared with the foot shock group ($P < 0.05$, Figure 4). These results confirm the success of the renal denervation surgical procedure.

3.5. Effect of Shock, Denervation, and Tempol Treatment on Plasma SOD and GSH-Px Activity and on TBARS Levels. The plasma SOD activity in the stress group was markedly reduced compared with the control group ($P < 0.05$, Figure 5(a)). The plasma SOD activity in the denervation plus shock and Tempol plus shock groups was markedly elevated compared with the foot shock group ($P < 0.05$, Figure 5(a)). The plasma GSH-Px activity in the foot shock group was also markedly higher than that of the control group ($P < 0.05$, Table 1).
Figure 2: Weight of thrombus. (a) Representative image of thrombus in each group. (b) Weight of thrombus was measured in each group after two-week stress as described in Materials and Methods section. Data of each group (n = 15) were presented as mean ± SEM. *P < 0.05 compared with control group. †P < 0.05 compared with stress group.

Figure 3: Platelet aggregation rate. Platelet aggregation rate stimulated by ADP (a, b) and platelet aggregation rate stimulated by collagen (c, d) were measured in each group after two-week stress as described in Materials and Methods section through platelet aggregation analyzer. (a) and (c) represent platelet aggregation trace provided by platelet aggregation analyzer. Data of each group (n = 15) were presented as mean ± SEM. *P < 0.05 compared with control group. †P < 0.05 compared with stress group.

Figure 5(b)). The plasma GSH-Px activity in the denervation plus shock and Tempol plus shock groups was markedly elevated compared with the foot shock group (P < 0.05, Figure 5(b)). Foot shock led to a marked increase in the levels of plasma thiobarbituric acid reactive substances (TBARS) compared with control group (P < 0.05, Figure 5(c)). The plasma TBARS levels in the denervation plus shock and Tempol plus
group. Compared with control group, stress condition is highly related to cardiovascular diseases. In addition, recent observations show that high pathetiesystem must play an important role in cardiovascular hypertension, and renal denervation is a new treatment in system activation is highly related to the development of stress? Since it has been demonstrated that renalsympathetic nerve system [7, 22]; the other is through activation of sympathetic-catecholamine, cortisol, vasopressin, endorphins, and aldos-

The phenomena of platelet adhesion, release, or aggregation are also known as platelet activation [29]. Activated platelets play an important role in the thrombosis process. Our data show that platelet aggregation increased after stress treatment, along with the enhancement in DVT formation. The platelet count was used to normalize the measure of platelet activity; however, no statistics on the number of platelets in each group were performed.

Our analyses of the plasma GSH-Px and SOD activity, as well as the plasma TBARS level, showed that the body is in a state of oxidative stress induced by chronic foot shock treatment, which was inhibited by renal denervation. Several reports have shown that NAD(P)H oxidase activity could be directly increased by the α1- and β2-receptors [30] through the catecholamines (CA) released by the renal sympathetic nerve. Moreover, β1-receptor antagonists were shown to reduce the vascular oxidative stress caused by NAD(P)H oxidase activation [31]. Therefore, we can say that the renal sympathetic innervation directly increases oxidative stress levels. It has been reported that platelet aggregation, an additional risk factor for thrombus, is associated with oxidative stress [32]. Oxidative stress could directly increase platelet aggregation through oxygen-free radicals located on the platelet surface [32]. Solid evidence has demonstrated that oxidative stress could directly activate platelets through a variety of ways. As the product of oxidative stress O₂⁻ could react with platelet or endothelium, then NO derived from ONOO⁻, which is of particular importance for vascular thrombosis, also has such effects. Several studies have shown that O₂⁻ could reduce the threshold for platelet activation to thrombin, collagen, or ADP and O₂⁻ may even be able to induce spontaneous aggregation [33–35]. The activated platelet even could produce ROS; the role of this endogenous ROS is similar to exogenous ROS in platelet activation. Generally, several scenarios leading to stress-induced platelet aggregation exist. In the first one, the renal sympathetic nerve is activated by stress, which leads to an increased oxidative stress throughout the body that is then followed by an increase in platelet aggregation. In the other scenario, stress directly triggers the body oxidative stress production, which directly increases platelet aggregation. Renal sympathetic

**Figure 4:** Plasma concentrations of noradrenaline. Concentrations of noradrenaline in plasma in each group after two-week stress were measured as described in Materials and Methods section. Data of each group ($n = 15$) were presented as mean ± SEM. *$P < 0.05$ compared with control group. †$P < 0.05$ compared with stress group.

Data clearly demonstrated the role of renal sympathetic nerve system in the chronic shock induced development of DVT, it is hard to identify whether afferent or efferent nerve plays a major role due to the limitation of surgical procedure. We speculate that both are involved in; the reason is that afferent nerve could affect neurogenic control of blood pressure which may contribute to the development of DVT; and efferent nerve could regulate renal secretion of noradrenalinewhich may also contribute to the development of DVT.

In this study, we identified that DVT formation is facilitated under stress conditions and that changes in the blood coagulation system are induced by stress. Accumulating data have shown that chronic psychological stress activated two systems: one is hypothalamus-pituitary-adrenal cortex (HPA) system which was mainly mediated by release of catecholamine, cortisol, vasopressin, endorphins, and aldosterone [7, 22]; the other is through activation of sympathetic-adrenal medullar system [22–25]. As shown in the data, the corticosterone levels of chronic shock group were significantly increased, indicating that HPA was activated. What is the role of sympathetic nerve system in response to stress? Since it has been demonstrated that renal sympathetic system activation is highly related to the development of hypertension, and renal denervation is a new treatment in clinical for refractory hypertension patients [26], renal sympathetic system must play an important role in cardiovascular diseases. In addition, recent observations show that high stress condition is highly related to cardiovascular diseases [4] especially cardiac and brain infarction; therefore, we speculate whether chronic stress will activate coagulation system through activation of renal sympathetic nervous system. In the present study, we firstly found that chronic stress could aggregate the DVT formation, suggesting that stress will increase the risk of cardiovascular diseases. In addition, we measured parameters defining the activity of the blood coagulation system, including PT, APPT, TT, and platelet aggregation. Our data showed that there was a significant change in platelet aggregation induced by both ADP and collagen suggesting that the aggravating effect of stress on DVT formation was mediated by activation of platelet. Our results firstly reveal the mechanism which links the high stress condition and cardiovascular diseases. Although our present

4. Discussion

In this study, we identified that DVT formation is facilitated under stress conditions and that changes in the blood coagulation system are induced by stress. Accumulating data have shown that chronic psychological stress activated two systems: one is hypothalamus-pituitary-adrenal cortex (HPA) system which was mainly mediated by release of catecholamine, cortisol, vasopressin, endorphins, and aldosterone [7, 22]; the other is through activation of sympathetic-adrenal medullar system [22–25]. As shown in the data, the corticosterone levels of chronic shock group were significantly increased, indicating that HPA was activated. What is the role of sympathetic nerve system in response to stress? Since it has been demonstrated that renal sympathetic system activation is highly related to the development of hypertension, and renal denervation is a new treatment in clinical for refractory hypertension patients [26], renal sympathetic system must play an important role in cardiovascular diseases. In addition, recent observations show that high stress condition is highly related to cardiovascular diseases [4] especially cardiac and brain infarction; therefore, we speculate whether chronic stress will activate coagulation system through activation of renal sympathetic nervous system. In the present study, we firstly found that chronic stress could aggregate the DVT formation, suggesting that stress will increase the risk of cardiovascular diseases. In addition, we measured parameters defining the activity of the blood coagulation system, including PT, APPT, TT, and platelet aggregation. Our data showed that there was a significant change in platelet aggregation induced by both ADP and collagen suggesting that the aggravating effect of stress on DVT formation was mediated by activation of platelet. Our results firstly reveal the mechanism which links the high stress condition and cardiovascular diseases. Although our present
nerve denervation may affect the platelet activation directly, however, the mechanism of which remains to be explored.

Our data showed that chronic stress treatment has no significant effect on either APPT or PT, suggesting that the stress-facilitated DVT may not be associated with the extrinsic or intrinsic coagulation system. Nevertheless, chronic stress treatment could markedly increase TT, which indicates that the conversion time of fibrinogen into fibrin was prolonged because of a hyperfibrinolysis. Hence, we speculate that fibrinolytic hyperfibrinolysis was due to an enhanced blood coagulation under the condition of chronic stress. Concurrently, the renal denervation and antioxidant treatment could decrease platelet aggregation, which in turn suppressed blood coagulation. Based on our data, we could observe that the TT tended towards a normal rate in these two conditions when compared with the shock group.

It should be noted that, in our present observation, we found that Tempol treatment could reduce chronic stress-induced increase of corticosterone levels, suggesting the involvement of oxidative stress in HPA activation induced hormone release, indicating that antioxidant treatment may provide some beneficial effects in HAP activation induced organ injury. However, we did not find any difference between denervation and antioxidant treatments in any parameters, indicating that sympathetic nerve and oxidative stress may independently contribute to the development of DVT induced by chronic shock.

In conclusion, chronic stress could increase platelet aggregation directly via the activation of the renal sympathetic nerve and increase of oxidative stress. Then, DVT comes to be facilitated by the increase in platelet aggregation. A number of studies have shown that atherosclerosis and other cardiovascular diseases are closely associated with oxidative stress [36] and that patients often present with low blood antioxidant levels [37] and enhanced levels of oxidative stress markers [38]. So, in view of the cardiocerebral vascular diseases and DVT, we can prevent and treat these diseases by targeting the therapy at the hormonal and antioxidant levels. In addition to this, it is a new way of therapy through renal sympathetic nerve.

**Conflict of Interests**

The authors declare no competing financial interests.

**Authors’ Contribution**

Guo-Xing Zhang conceived of and designed the experiments. Tao Dong, Yu-Wen Cheng, Pei-Wen Sun, and Chen-Jie Zhu performed the experiments. Fei Yang assisted with platelet aggregation. Guo-Xing Zhang contributed reagents/materials and analyzed data. Guo-Xing Zhang, Tao Dong, and Yu-Wen Cheng wrote the paper.
Acknowledgments
The authors are grateful to Professor Li Zhu and other members of the Zhu laboratory for experimental advice and assistance. This work was supported by the National Natural Science Foundation of China (81270316, 81470563) and the Research Program of Soochow University (Q413400111).

References
[1] P. Aranda-Lara, M. D. Martínez-Estebar, J. J. Muñoz, and D. Hernández-Marrero, “Renal sympathetic denervation: a new treatment strategy in the management of refractory arterial hypertension,” *Nefrologia*, vol. 32, no. 5, pp. 555–557, 2012.
[2] J. M. Herbert, A. Bernat, and J. P. Maffrand, “Importance of platelets in experimental venous thrombosis in the rat,” *Blood*, vol. 80, no. 9, pp. 2281–2286, 1992.
[3] M. Nusair, A. Al-dadah, and A. Kumar, “The tale of mind & heart: psychiatric disorders & coronary heart disease,” *Missouri Medicine*, vol. 109, no. 3, pp. 199–203, 2012.
[4] S. Neelakantan, “Psychology: mind over myocardium,” *Nature*, vol. 493, no. 7434, pp. S16–S17, 2013.
[5] M. R. W. Brown and A. W. Smith, “Dormancy and persistence in chronic infection: role of the general stress response in resistance to chemotherapy,” *Journal of Antimicrobial Chemotherapy*, vol. 48, no. 1, pp. 141–142, 2001.
[6] M. Tanaka, “Emotional stress and characteristics of brain noradrenaline release in the rat,” *Industrial Health*, vol. 37, no. 2, pp. 143–156, 1999.
[7] L. M. Lu, J. Wang, and T. Yao, “Angiotensin II participates in stress-induced high blood pressure via stimulating hypothalamic vasopressin synthesis and release,” *Acta Physiologica Sinica*, vol. 52, no. 5, pp. 371–374, 2000.
[8] Z. S. Lj and X. Y. Liu, “Depressor effect of nucleus arcuatus stimulation in chronic stress-induced hypertensive rat,” *Acta Physiologica Sinica*, vol. 44, no. 2, pp. 133–141, 1992.
[9] C. M. Xia, C. H. Shao, L. Xin et al., “Effects of melatonin on blood pressure in stress-induced hypertension in rats,” *Clinical and Experimental Pharmacology and Physiology*, vol. 35, no. 10, pp. 1258–1264, 2008.
[10] H. Kirchheim, H. Ehmke, and P. Persson, “Sympathetic modulation of renal hemodynamics, renin release and sodium excretion,” *Klinische Wochenschrift*, vol. 67, no. 17, pp. 858–864, 1989.
[11] V. Kon, “Neural control of renal circulation,” *Mineral and Electrolyte Metabolism*, vol. 15, no. 1-2, pp. 33–43, 1989.
[12] P. A. Sobotka, F. Mahfoud, M. P. Schlaich, M. Böhm, and H. Krum, “Sympatho-renal axis in chronic disease,” *Clinical Research in Cardiology*, vol. 100, no. 12, pp. 1049–1057, 2011.
[13] F. Mahfoud, T. F. Lüscher, B. Andersson et al., “Expert consensus document from the European Society of Cardiology on catheter-based renal denervation,” *European Heart Journal*, vol. 34, no. 28, pp. 2149–2157, 2013.
[14] C. Ukena, A. Bauer, F. Mahfoud et al., “Renal sympathetic denervation for treatment of electrical storm: first-in-man experience,” *Clinical Research in Cardiology*, vol. 101, no. 1, pp. 63–67, 2012.
[15] T. J. Guzik, N. E. West, E. Black et al., “Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors,” *Circulation Research*, vol. 86, no. 9, pp. E85–E90, 2000.
[16] D. N. Granger, S. F. Rodrigues, A. Yildirim, and E. Y. Senchenkova, “Microvascular responses to cardiovascular risk factors,” *Microcirculation*, vol. 17, no. 3, pp. 192–205, 2010.
[17] P. Minuz, P. Patrignani, S. Gaino et al., “Determinants of platelet activation in human essential hypertension,” *Hypertension*, vol. 43, no. 1, pp. 64–70, 2004.
[18] G.-X. Zhang, K. Ohmori, Y. Nagai et al., “Role of AT1 receptor in isoproterenol-induced cardiac hypertrophy and oxidative stress in mice,” *Journal of Molecular and Cellular Cardiology*, vol. 42, no. 4, pp. 804–811, 2007.
[19] R. J. Bolterman, M. C. Manriquez, M. C. Ortiz Ruiz, L. A. Juncos, and J. C. Romero, “Effects of captopril on the renin angiotensin system, oxidative stress, and endothelin in normal and hypertensive rats,” *Hypertension*, vol. 46, no. 4, pp. 943–947, 2005.
[20] M. Yoshiyama, K. Takeuchi, T. Omura et al., “Effects of candesartan and cilazapril on rats with myocardial infarction assessed by echocardiography,” *Hypertension*, vol. 33, no. 4, pp. 961–968, 1999.
[21] P. S. Leung, “The peptide hormone angiotensin II: its new functions in tissues and organs,” *Current Protein and Peptide Science*, vol. 5, no. 4, pp. 267–273, 2004.
[22] R. S. Zimmerman and E. D. Frohlich, “Stress and hypertension,” *Journal of Hypertension*, vol. 8, no. 4, pp. S103–S107, 1990.
[23] E. A. Anderson, C. A. Sinkey, and A. L. Mark, “Mental stress increases sympathetic nerve activity during sustained baroreceptor stimulation in humans,” *Hypertension*, vol. 17, no. 4, pp. I-43–I-49, 1991.
[24] B. G. Wallin, W. Delius, and K. E. Hagbarth, “Comparison of sympathetic nerve activity in normotensive and hypertensive subjects,” *Circulation Research*, vol. 33, no. 1, pp. 9–21, 1973.
[25] P. Mustacchi, “Stress and hypertension,” *Western Journal of Medicine*, vol. 153, no. 2, pp. 180–185, 1990.
[26] G. Grassi, A. Mark, and M. Esler, “The sympathetic nervous system alterations in human hypertension,” *Circulation Research*, vol. 116, no. 6, pp. 976–990, 2015.
[27] M. Brozovic, “Mechanisms of deep vein thrombosis: a review,” *Journal of the Royal Society of Medicine*, vol. 72, no. 8, pp. 602–605, 1979.
[28] S. P. Jackson, “The growing complexity of platelet aggregation,” *Blood*, vol. 109, no. 12, pp. 5087–5095, 2007.
[29] D. L. Musselman, U. Marzec, M. Davidoff et al., “Platelet activation and secretion in patients with major depression, thoracic aortic atherosclerosis, or renal dialysis treatment,” *Depression and Anxiety*, vol. 15, no. 3, pp. 91–101, 2002.
[30] J. E. Faber, C. L. Szymeczek, S. S. Salvi, and H. Zhang, “Enhanced α1-adrenergic trophic activity in pulmonary artery of hypoxic pulmonary hypertensive rats,” *American Journal of Physiology: Heart and Circulatory Physiology*, vol. 291, no. 5, pp. H2272–H2281, 2006.
[31] M. Oelze, A. Daiber, R. P. Brandes et al., “Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats,” *Hypertension*, vol. 48, no. 4, pp. 677–684, 2006.
[32] M. Aviram, “LDL-platelet interaction under oxidative stress in tissues and organs,” *Current Protein and Peptide Science*, vol. 5, no. 4, pp. 267–273, 2004.
[33] J. P. de la Cruz, P. J. Garcia, and F. S. de la Cuesta, “Dipyridamole inhibits platelet aggregation induced by oxygen-derived free radicals,” *Thrombosis Research*, vol. 66, no. 4, pp. 277–285, 1992.
[34] R. I. Handin, R. Karabin, and G. J. Boxer, “Enhancement of platelet function by superoxide anion,” *Journal of Clinical Investigation*, vol. 59, no. 5, pp. 959–965, 1977.

[35] D. Salvemini, G. De Nucci, J. M. Sneddon, and J. R. Vane, “Superoxide anions enhance platelet adhesion and aggregation,” *British Journal of Pharmacology*, vol. 97, no. 4, pp. 1145–1150, 1989.

[36] H. Mangge, “Antioxidants, inflammation and cardiovascular disease,” *World Journal of Cardiology*, vol. 6, no. 6, pp. 462–477, 2014.

[37] C. Murr, B. M. Winkelhofer-Roob, K. Schroecksnadel et al., “Inverse association between serum concentrations of neopterin and antioxidants in patients with and without angiographic coronary artery disease,” *Atherosclerosis*, vol. 202, no. 2, pp. 543–549, 2009.

[38] D. Fuchs, P. Avanzas, R. Arroyo-Espliguero, M. Jenny, L. Consuegra-Sanchez, and J. C. Kaski, “The role of neopterin in atherogenesis and cardiovascular risk assessment,” *Current Medicinal Chemistry*, vol. 16, no. 35, pp. 4644–4653, 2009.